Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05813288
Other study ID # AR-DEX-22-02
Secondary ID 2023-503693-20
Status Recruiting
Phase Phase 3
First received
Last updated
Start date March 27, 2023
Est. completion date July 2026

Study information

Verified date February 2024
Source Areteia Therapeutics
Contact EXHALE Recruiting
Phone 888-584-9281
Email clinicaltrials@areteiatx.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this clinical study is to investigate the safety, tolerability, and efficacy of dexpramipexole in participants with inadequately controlled severe eosinophilic asthma.


Recruitment information / eligibility

Status Recruiting
Enrollment 930
Est. completion date July 2026
Est. primary completion date June 2026
Accepts healthy volunteers No
Gender All
Age group 12 Years to 99 Years
Eligibility Inclusion Criteria: 1. Signed informed consent form and assent form, as appropriate. 2. Male or female =12 years of age at Screening Visit 1. Asthma-related criteria 3. Documented physician diagnosis of asthma for =12 months prior to Screening Visit 1. 4. Eosinophil count of =0.30x10?/L at Screening Visit 1. If the initial value is between 0.250x10?/L to 0.299x10?/L, then this may be repeated once at an unscheduled visit (prior to Screening Visit 2). 5. Treatment of asthma, participants must satisfy all the below (items a to c): 1. Participants who have received asthma controller medication with medium or high dose inhaled corticosteroids (ICS =500 µg/day fluticasone propionate dry powder formulation daily or clinically comparable, per GINA 2021) on a regular basis for at least 12 months prior to Screening Visit 1. 2. Documented treatment with a stable dose of either medium or high dose ICS for at least 3 months prior to Visit 1. The ICS may be contained within an ICS/long-acting ß2 agonist (LABA) combination product. Daily oral corticosteroids are an allowed concomitant medication; participants on daily oral corticosteroids must be on a stable dose for 3 months before Screening Visit 1. 3. Use of one of more additional daily maintenance asthma controller medications according to standard practice of care is required. Use of a stable dose of any additional asthma controller medications must be documented for at least 3 months prior to Screening Visit 1. 6. Pre-BD FEV1 =40% and <80% (<90% for participants 12 to 17 years of age) of predicted at Screening Visit 2. 7. Variable airflow obstruction documented with at least one of the following criteria: 1. Bronchodilator reversibility at Screening Visit 2, as evidenced by =12% and =200 mL improvement in FEV1, 15 to 30 minutes following inhalation of 400 µg (four puffs) of albuterol/salbutamol (=12% and =160 mL for ages 12 to 17). Participants who do not meet the bronchodilator reversibility inclusion criterion but have =10% and =160 mL reversibility, may repeat the reversibility spirometry assessment once during the Screening period, at an unscheduled visit at least 7 days prior to baseline. 2. Bronchodilator reversibility, using the criteria above, documented in the past 24 months prior to Screening Visit 1. 3. Peak flow variation of =20% over a 2-week period, documented in the past 24 months prior to Screening Visit 1. 4. Airflow variability in clinic FEV1 =20% between two consecutive clinic visits, documented in the past 24 months prior to Screening Visit 1. 5. Airway hyperresponsiveness (provocative concentration causing a 20% fall in FEV1 of methacholine <8 mg/mL) documented in the past 24 months prior to Screening Visit 1. 8. ACQ-6 =1.5 at Screening Visit 2. 9. Documented history of at least two asthma exacerbations requiring treatment with systemic corticosteroids (intramuscular, intravenous, or oral) within the past 12-month period prior to Screening Visit 1. General medical history 10. Negative urine pregnancy test for women of childbearing potential (WOCBP; after menarche) at the Screening and Baseline visits. 11. WOCBP must use either of the following methods of birth control, from Screening Visit 1 through the End of Study Visit: 1. A highly effective form of birth control (confirmed by the investigator). Highly effective forms of birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective Intrauterine device (IUD), IUD/intrauterine system (IUS), Levonorgestrel Intrauterine system, or oral contraceptive. - Or 2. Two protocol acceptable methods of contraception in tandem. Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrheic for =12 months prior to the planned date of the Baseline Visit without an alternative medical cause. The following age specific requirements apply: 3. Women <50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatment and follicle stimulating hormone levels in the postmenopausal range. 4. Women =50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatment. Exclusion Criteria: Asthma-related criteria 1. A participant who experiences a severe asthma exacerbation (defined as a deterioration of asthma that results in emergency treatment, hospitalization due to asthma, or treatment with systemic corticosteroids) at any time from 4 weeks prior to Screening Visit 1 up to and including the Baseline Visit. Participants who experience an asthma exacerbation during the Screening/Run-in Period may remain in screening and proceed with study visits 14 days after they have completed their course of oral steroids or returned to their pre-Screening Visit maintenance dose of oral steroids and the investigator considers participant has returned to baseline status. 2. Current diagnosis of diseases which may confound interpretation of this study's findings such as allergic bronchopulmonary aspergillosis, eosinophilic granulomatosis with polyangiitis, eosinophilic gastrointestinal diseases, hypereosinophilic syndrome, or lung diseases (eg, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis). 3. Respiratory infection: Upper or lower respiratory tract, sinus, or middle ear infection within the 4 weeks before Screening Visit 1. Prohibited medications/procedures 4. Treatment with a biologic investigational drug in the last 5 months prior to Screening Visit 1. Treatment with non-biologic investigational drugs in the previous 30 days or five-half-lives prior to Screening Visit 1, whichever is longer. Treatment with GSK3511294 (long-acting anti-IL-5) in the past 12 months. 5. Treatment with any of the following monoclonal antibody therapies within 120 days prior to Baseline: benralizumab, dupilumab, mepolizumab, reslizumab, omalizumab, tezepelumab, or tralokinumab. 6. Treatment with pramipexole (Mirapex®) within 30 days of Baseline. 7. Treatment with selected drugs known to have a substantial risk of neutropenia in the past 30 days prior to Screening Visit 1. 8. Bronchial thermoplasty procedure in the past 12 months prior to Screening Visit 1 or planned during the coming year. General medical history 9. Weight <40 kg at Screening Visit 1. 10. Current smoking within 12 months prior to Screening Visit 1 or a smoking history of >10 pack-years. Smoking includes tobacco, vaping, and/or marijuana use. 11. Known or suspected alcohol or drug abuse 12. Uncontrolled severe hypertension: systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg prior to Baseline Visit despite anti-hypertensive therapy. 13. History of malignancy that required surgery (excluding local and wide-local excision), radiation therapy and/or systemic therapy during the 5 years prior to Baseline Visit. 14. History of human immunodeficiency virus (HIV) infection or chronic infection with hepatitis B or C. 15. A helminth parasitic infection diagnosed within 24 weeks prior Screening Visit 1 that has not been treated with or has failed to respond to standard of care (SoC) therapy. 16. Medical or other condition likely to interfere with participant's ability to undergo study procedures, adhere to visit schedule, or comply with study requirements. 17. Known or suspected noncompliance with medication. 18. Unwillingness or inability to follow the procedures outlined in the protocol. Clinical safety labs 19. Absolute neutrophil count <2.000x10?/L at screening at Screening Visit 1 or Screening Visit 2. 20. Renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m² at Screening Visit 2 (using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula [Levey et al, 2009] for age =18 years at screening; using the Bedside Schwartz [Schwartz and Work, 2009] eGFR formula for age <18). 21. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), >3x the upper limit of normal (ULN), or total bilirubin >2x ULN at Screening Visit 2 confirmed by a repeat abnormal measurement of the relevant value(s), at least 1 week apart. Cardiac safety 22. History of New York Heart Association class IV heart failure or last known left ventricular ejection fraction <25%. 23. History of major adverse cardiovascular event (MACE) within 3 months prior to the Baseline Visit. 24. History of cardiac arrhythmia within 3 months prior to Baseline Visit that is not controlled by medication or via ablation. 25. History of long QT syndrome. 26. Corrected QT interval by Fridericia (QTcF) interval >450 ms for males and >470 ms for females at Screening Visit 2 or QTcF =480 ms for participants with bundle branch block. 27. Clinically important abnormalities in resting ECG that may interfere with the interpretation of QTcF interval changes at Screening Visit 2, including heart rate <45 beats per minute (bpm) or >100 bpm. Pregnancy/Lactation 28. Pregnant women or women breastfeeding. 29. Males who are unwilling to use an acceptable method of birth control during the entire study period (ie, condom with spermicide).

Study Design


Intervention

Drug:
Dexpramipexole Dihydrochloride
Oral administration of dexpramipexole tablet
Placebo
Oral administration of placebo tablet

Locations

Country Name City State
Korea, Republic of Research Site 30082-017 Wonju
South Africa Research Site 30027-013 Benoni
South Africa Research Site 30027-009 Cape Town
South Africa Research Site 30027-011 Cape Town
South Africa Research Site 30027-001 Durban
South Africa Research Site 30027-010 Durban
South Africa Research Site 30027-014 Durban
South Africa Research Site 30027-007 KwaZulu
South Africa Research Site 30027-008 KwaZulu
United Kingdom Research Site 30044-027 Glasgow
United Kingdom Research Site 30044-059 High Wycombe
United Kingdom Research Site 30044-025 Sheffield
United States Research Site 30001-334 Allen Texas
United States Research Site 30001-090 Austin Texas
United States Research Site 30001-290 Austin Texas
United States Research Site 30001-363 Edison New Jersey
United States Research Site 30001-299 Houston Texas
United States Research Site 30001-291 Jacksonville Florida
United States Research Site 30001-315 Katy Texas
United States Research Site 30001-286 Lafayette Louisiana
United States Research Site 30001-366 Lilburn Georgia
United States Research Site 30001-010 Little Rock Arkansas
United States Research Site 30001-318 Maitland Florida
United States Research Site 30001-313 Marrero Louisiana
United States Research Site 30001-295 McKinney Texas
United States Research Site 30001-373 Mesquite Texas
United States Research Site 30001-082 Miami Florida
United States Research Site 30001-288 Miami Florida
United States Research Site 30001-310 Miami Florida
United States Research Site 30001-311 Miami Florida
United States Research Site 30001-331 Miami Florida
United States Research Site 30001-287 Mobile Alabama
United States Research Site 30001-301 Naples Florida
United States Research Site 30001-348 Ocala Florida
United States Research Site 30001-293 Orlando Florida
United States Research Site 30001-331 Orlando Florida
United States Research Site 30001-297 Pearland Texas
United States Research Site 30001-312 Pembroke Pines Florida
United States Research Site 30001-333 Pleasant View Utah
United States Research Site 30001-238 San Antonio Texas
United States Research Site 30001-377 San Antonio Texas
United States Research Site 30001-300 Schenectady New York
United States Research Site 30001-335 Sugar Land Texas
United States Research Site 30001-305 Valencia California
United States Research Site 30001-319 Viera Florida
United States Research Site 30001-372 Warren Michigan

Sponsors (1)

Lead Sponsor Collaborator
Areteia Therapeutics

Countries where clinical trial is conducted

United States,  Korea, Republic of,  South Africa,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Annualized rate of severe asthma exacerbations over 52 weeks. A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for >=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids; or death due to asthma. Day 1 (baseline, pre-dose) through Week 52
Secondary Absolute Change in pre-bronchodilator forced expiratory volume (Pre-BD FEV1) from Baseline The absolute change from baseline in pre-bronchodilator forced expiratory volume, averaged across visits at Weeks 36, 44, and 52. Day 1 (baseline, pre-dose), Weeks 36, 44, 52
Secondary Mean Change From Baseline at Week 52 in Asthma Control Questionnaire-6 (ACQ-6) (Key Secondary Endpoint) Change from baseline in ACQ-6 as compared to placebo at Week 52. The ACQ-6 captures asthma symptoms and short-acting ß2-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses From randomization to Study Week 52
Secondary Mean Change From Baseline at Week 52 in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ+12) Total Score (Key Secondary Endpoint) Mean change from baseline in AQLQ+12 as compared to placebo at Week 52. The AQLQ+12 is a questionnaire that measures the health-related quality of life experienced by asthma subjects. The total score is defined as the average of all 32 questions in the AQLQ+12 questionnaire. AQLQ+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). From randomization to Study Week 52
Secondary Annualized rate of severe exacerbations requiring an emergency over 52 weeks department visit or hospitalization Day 1 (baseline, pre-dose), Week 52
Secondary Annualized rate of severe exacerbations (AAER) from Week 4 to Week 52. Week 4 through Week 52
Secondary Change in absolute eosinophil count (AEC) Day 1 (baseline, pre-dose), Week 52
Secondary Average change from baseline in forced vital capacity (FVC) Day 1(baseline, pre-dose), Weeks 36, 44, and 52
Secondary FVC, change from baseline at Weeks 4, 12, 20, 28, 36, 44, and 52. Day 1(baseline, pre-dose), Weeks 4, 12, 20, 28, 36, 44, and 52.
Secondary Post-bronchodilator FEV1, change from baseline to Week 52 Day 1 (baseline, pre-dose) through Week 52
Secondary Time to first severe asthma exacerbation Up to Week 52
Secondary Mean Change From Baseline at Week 52 in Asthma Symptom Diary (ASD) The Asthma Symptom Diary comprises of 10 items (5 items in the morning; 5 items in the evening). Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the daily diary. A daily ASD score is the mean of the 10 items. Responses for all 10 items are required to calculate the daily ASD score; otherwise, it is treated as missing. For the 7-day average asthma symptom score, scoring is done with no imputation using the mean of at least 4 of the 7 daily ASD scores as a mean weekly item score. The 7-day average ASD score ranges from 0 to 4, where 0 indicates no asthma symptoms. From randomization to Study Week 52
Secondary Mean Change From Baseline at Week 52 in EQ-5D-5L EQ-5D-5L allows subjects to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state. At Study Week 52
See also
  Status Clinical Trial Phase
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device